GSA Capital Partners LLP Lowers Holdings in BioCryst Pharmaceuticals, Inc. $BCRX

GSA Capital Partners LLP cut its holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 43.1% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 108,229 shares of the biotechnology company’s stock after selling 82,065 shares during the period. GSA Capital Partners LLP’s holdings in BioCryst Pharmaceuticals were worth $844,000 as of its most recent SEC filing.

Other large investors also recently added to or reduced their stakes in the company. Larson Financial Group LLC lifted its holdings in BioCryst Pharmaceuticals by 1,188.0% in the 4th quarter. Larson Financial Group LLC now owns 3,542 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 3,267 shares in the last quarter. Focus Partners Wealth purchased a new position in BioCryst Pharmaceuticals in the 3rd quarter worth approximately $77,000. Mirae Asset Global Investments Co. Ltd. lifted its holdings in BioCryst Pharmaceuticals by 26.1% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 10,231 shares of the biotechnology company’s stock worth $80,000 after purchasing an additional 2,115 shares in the last quarter. Vestmark Advisory Solutions Inc. purchased a new position in BioCryst Pharmaceuticals in the 3rd quarter worth approximately $81,000. Finally, Envestnet Portfolio Solutions Inc. purchased a new position in BioCryst Pharmaceuticals in the 4th quarter worth approximately $81,000. 85.88% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research analysts recently commented on the company. Wall Street Zen cut BioCryst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Saturday, May 9th. Weiss Ratings raised BioCryst Pharmaceuticals from a “sell (d-)” rating to a “hold (c)” rating in a report on Wednesday, March 4th. Evercore assumed coverage on BioCryst Pharmaceuticals in a report on Wednesday, February 18th. They set an “outperform” rating and a $17.00 price objective on the stock. Royal Bank Of Canada decreased their price objective on BioCryst Pharmaceuticals from $14.00 to $13.00 and set an “outperform” rating on the stock in a report on Friday, January 30th. Finally, Citizens Jmp upped their price objective on BioCryst Pharmaceuticals from $25.00 to $28.00 and gave the stock a “market outperform” rating in a report on Thursday, May 7th. Nine research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $20.70.

Insiders Place Their Bets

In related news, insider Alane P. Barnes sold 150,000 shares of the stock in a transaction on Monday, March 16th. The stock was sold at an average price of $9.15, for a total transaction of $1,372,500.00. Following the sale, the insider owned 400,703 shares in the company, valued at approximately $3,666,432.45. This represents a 27.24% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders own 5.10% of the company’s stock.

BioCryst Pharmaceuticals Stock Performance

NASDAQ:BCRX opened at $8.29 on Friday. The stock’s fifty day moving average is $9.16 and its 200 day moving average is $7.95. BioCryst Pharmaceuticals, Inc. has a fifty-two week low of $6.00 and a fifty-two week high of $11.31. The firm has a market capitalization of $2.11 billion, a PE ratio of -4.66 and a beta of 0.57.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported ($2.98) earnings per share for the quarter, missing the consensus estimate of $0.06 by ($3.04). BioCryst Pharmaceuticals had a negative net margin of 51.71% and a negative return on equity of 76.36%. The company had revenue of $156.41 million for the quarter, compared to analysts’ expectations of $151.12 million. During the same quarter in the previous year, the company posted $0.20 EPS. The business’s quarterly revenue was up 7.5% on a year-over-year basis. Equities analysts forecast that BioCryst Pharmaceuticals, Inc. will post -2.66 EPS for the current year.

BioCryst Pharmaceuticals Profile

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.